Liberia

NEW YORK - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday.

The two vaccines, each given in a single injection, are being tested for safety and efficacy on more than 600 people in Liberia in a mid-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a branch of NIH.

The Ebola epidemic that began in West Africa one year ago has killed more than 10,200 people, but a decline in new cases in the most affected countries, Liberia, Guinea and Sierra Leone, has led to hopes that it may be ending.

Based on the encouraging safety results, the study may now advance to the next phase of efficacy testing, in which additional volunteers are injected with the GSK vaccine, the NewLink vaccine, or a dummy shot and assessed to see whether their immune system responds by producing anti-Ebola antibodies.

SCIENCE NEWS  by Ashley Yaeger                                                      March 26, 2015

(Scroll down for full study.)

The virus causing the current Ebola epidemic in West Africa is not evolving as quickly as some scientists had suggested.

REGULAR RATE  A genetic analysis suggests that the Ebola virus, shown here in orange, is not evolving as fast as expected.

In a paper last August, researchers reported that the virus (Zaire ebolavirus) was altering its genes almost twice as fast as it had during previous Ebola outbreaks in Central Africa (SN: 9/20/14, p. 7). However, a new genetic analysis shows that the virus is mutating at roughly the same rate as in past outbreaks, researchers report online March 26 in Science. The finding suggests the virus has not become more virulent or transmissible during the West Africa outbreak.

NATIONAL PUBLIC RADIO  by Poncie Rutsch                                                      March 25, 2015
From more than 900 miles away, Kpetermeni Siakor helped get volunteers to the right neighborhoods in his native Liberia during the height of the Ebola epidemic.

Kpetermeni Siakor (left), a Liberian who is studying in Ghana, used crowdsourcing software to help out during the Ebola epidemic. Courtesy of Ashesi University College

He did it with Ushahidi, crowdsourcing software that was developed in Kenya in 2008, when the country experienced a wave of post-election violence. The word Ushahidi means testimony in Swahili.

"The government had shut down internet connections and radio stations, so Ushahidi was born out of the need to let people know what is happening," says Siakor, 26. He's a computer science student at Ashesi University College in Accra, Ghana, and receives financial support from the MasterCard Foundation Scholars Program.

LIVE SCIENCE       by Agata Blaszczak Boxe                                               March 25, 2015

Young children who are infected with Ebola may be more likely to die from the virus than older children or adults who are infected, according to a new study.

The disease has killed about 90 percent of infected children under age 1, and about 80 percent of kids ages 1 to 4 who have been infected. Older children who have been infected with Ebola may have a much better chance of surviving....

"The very youngest of children — neonates  —appear to have the worst outcomes from Ebola," study co-author Dr. Robert Fowler, an associate professor of critical-care medicine at the University of Toronto, said in a statement. (Neonates, or newborns, are babies younger than 1 month.)